AVP and stroke disorder: Furthermore, Ahmed et al. also proved the greater value of copeptin compared to troponin I for NSTEMI patients and its prognostic value for MACEs (cardiac death, re-infarction, re-hospitalization for ischemic events, HF, stroke and TLR) and coronary revascularization within one year of follow-up (p < 0.001 for each) [67].